An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment

Completed · Phase 1

Conditions studied: Advanced Cancer

In brief

The purpose of this study is to evaluate the treatment of solid tumors with various immunotherapy combinations. The treatment will be determined based upon a broad biomarker assessment.

Key facts

Study ID

NCT03335540

Run by

Bristol-Myers Squibb

People needed

20

Starts

2018-05-07

Expected to finish

2021-08-25

Last updated by the study team

2022-09-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must have an ECOG performance status of less than or equal to 1
• Participants must have had prior therapy;Participants who have received adjuvant or neoadjuvant anti-PD(L)1 therapy andprogressed within 6 months of completing therapy will be considered IO refractory.
• Participants must have at least 2 lesions with measurable disease as defined by RECIST Version 1.1

You may not qualify if…

• Participants with suspected, known, or progressive CNS metastases, have untreated CNS metastases, or have the CNS as the only site of disease
• Participants with carcinomatous meningitis
• Participants with other active malignancy requiring concurrent intervention
• Other protocol defined inclusion/exclusion criteria could apply

Where it is running

• Local Institution - 0001 — Chicago, Illinois, United States
• University of Chicago — Chicago, Illinois, United States
• Local Institution - 0002 — Baltimore, Maryland, United States
• Local Institution - 0003 — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.